近日，悦康药业集团正式向香港联合交易所（港交所）提交了主板上市申请，拟通过此次IPO募集资金用于研发创新药物、扩大生产规模及拓展国际市场。作为中国领先的综合性制药企业之一，悦康药业专注于化学药、中药、生物药等多个领域，拥有覆盖全国的销售网络和多个GMP认证生产基地。公司近年来持续加大研发投入，已有多款新药进入临床试验阶段，并积极布局抗感染、心脑血管、肿瘤等治疗领域。此次赴港上市，不仅有助于提升其资本实力和品牌国际影响力，也将为其全球化战略提供重要支撑。值得注意的是，悦康药业此前已于2020年在上海证券交易所科创板成功上市，此次港股IPO标志着其开启“A+H”双资本平台的新阶段，有望进一步优化融资结构、增强市场竞争力。
Recently, Yuekang Pharmaceutical Group has officially submitted an application for a main board listing on the Hong Kong Stock Exchange (HKEX). The company plans to use the proceeds from this IPO to fund innovative drug R&D, expand production capacity, and broaden its international footprint. As one of China’s leading integrated pharmaceutical companies, Yuekang focuses on multiple therapeutic areas including chemical drugs, traditional Chinese medicine, and biologics. It operates a nationwide sales network and several GMP-certified manufacturing facilities. In recent years, Yuekang has significantly increased its R&D investment, with multiple new drug candidates now in clinical trials, particularly in anti-infective, cardiovascular, and oncology therapies. The Hong Kong listing is expected to enhance the company’s capital strength and global brand recognition, providing crucial support for its international expansion strategy. Notably, Yuekang was already listed on the STAR Market of the Shanghai Stock Exchange in 2020; this HKEX application marks its move toward a dual “A+H” listing structure, which could further optimize its financing framework and strengthen market competitiveness.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/7453.html